Anti-Bcl2 alpha antibody [SP66] - N-terminal,Abcam,AB93884

What is this antibody validated in? Anti-Bcl2 alpha antibody [SP66] - N-terminal (ab93884) is a rabbit recombinant monoclonal antibody and is validated for use in Immunohistochemistry (IHC-P) in Human samples. Collaboration Anti-Bcl2 alpha [SP66] - N-terminal (ab93884) is a clone from the portfolio of Spring Bioscience (Roche) SP clones which have been optimised for immunohistochemistry (IHC). Other related products We have a range of other formats of antibody clone [SP66] also available for your convenience: ab93884, Carrier free - ab236221 , ab279431

Host

Rabbit

Reactivity

Human

Application

IHC-P

Platform ID

BAB847849832

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-Bcl2 alpha antibody [SP66] - N-terminal
Cat. No.AB93884
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationIHC-P
ClonalityMonoclonal
Clone NumberSP66
Concentration0.075 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A/G
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.6 Preservative: 0.1% Sodium azide Constituents: PBS, 1% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells (PubMed : 1508712, PubMed : 8183370). Regulates cell death by controlling the mitochondrial membrane permeability (PubMed : 11368354). Appears to function in a feedback loop system with caspases (PubMed : 11368354). Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1) (PubMed : 11368354). Also acts as an inhibitor of autophagy : interacts with BECN1 and AMBRA1 during non-starvation conditions and inhibits their autophagy function (PubMed : 18570871, PubMed : 20889974, PubMed : 21358617). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed : 17418785). See full target information BCL2

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.